Daunorubicin HCl / Hydrochloride Powder CAS 23541-50-6 Raw Material

CAS: 23541-50-6

MF: C27H30ClNO10

MW: 563.98

EINECS: 245-723-4

Specification​: 99% min Daunorubicin HCl

Sample: Daunorubicin HCl Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Daunorubicin HCl Powder Usage and Synthesis.

Daunorubicin HCl Powder is a first generation anthracycline antibiotic used in haematology to treat acute granulocytic leukaemia, acute lymphoblastic leukaemia and acute monocytic leukaemia. Daunorubicin Hydrochloride Powder is a first-generation anthracycline antibiotic, and is used in haematology to treat acute granulocytic leukaemia, acute lymphoblastic leukaemia and acute monocytic leukaemia. Daunorubicin HCl Raw Material can be used clinically in combination with prednisone, cytarabine or vincristine to increase its antitumour effect.

Uses and functions of Daunorubicin HCl Powder.

Daunorubicin Hydrochloride Powder is used clinically in combination with prednisone, cytarabine or vincristine to increase its antitumour effect, in addition to the treatment of acute and chronic leukaemia. It is widely used in molecular biology, pharmacology and other scientific research. Daunorubicin Hydrochloride Powder is used in neuroblastoma and rhabdomyosarcoma.

Daunorubicin Hydrochloride is used in acute granulocytic leukaemia and acute lymphoblastic leukaemia, as well as in those with chronic acute changes.

Daunorubicin Hydrochloride is administered intravenously or as an intravenous drip. Dissolve with 10 ml of saline for injection before use. For intravenous drip, dissolve 250ml of 0.9% sodium chloride injection and drip within 1 hour. The dosage for a course of treatment is 0.4 to 1.0mg/kg for adults and 1.0mg/kg for children, once a day for 3 to 5 times, administered continuously or every other day. Repeat after 1 week of discontinuation. Total dose should not exceed 25mg/kg.

Pharmacological Effects of Daunorubicin HCl Powder.

Daunorubicin HCl Powder exhibits cytotoxic effects and is a cell cycle non-specific drug, which is inserted into the target cell between adjacent base pairs of DNA, generating reactive free radicals, causing DNA double-stranded helix unspin, DNA strand breakage, inhibiting the template activity of nucleic acids, interfering with the transcription process, preventing mRNA synthesis and reaching the tissue cells for replication. Daunorubicin HCl Powder may also cause cell membrane rupture, which in turn may lead to cell death, thus exerting a medicinal effect.

Erythromycin is a cyclic non-specific antitumour agent and animal tests have shown it to have a life-prolonging effect on mouse L1210 leukaemia and has shown some efficacy against aminomethylfolate, 6-mercaptopurine and 5-fluorouracil resistant cell lines. In addition, it has shown life-prolonging effects in Yoshida sarcoma rats and has shown some efficacy against cyclophosphamide, triethylenethiophosphamide, 6-mercaptopurine, 5-chlorouracil, mitomycin C and chromogranin A3 resistant cell lines. The mechanism of action of erythromycin lies in the nucleic acid synthesis process of the cells, which binds directly to DNA and prevents DNA synthesis and DNA-dependent RNA synthesis reactions.

Production method of Daunorubicin HCl Powder.

Daunorubicin HCl is a cyclic non-specific antitumour agent that has been shown in animal studies to have a life-prolonging effect in murine L1210 leukaemia and has shown some efficacy against aminomethylfolate, 6-mercaptopurine and 5-fluorouracil resistant cell lines.

In addition, it has shown life-prolonging effects in Yoshida sarcoma rats and has shown some efficacy against cyclophosphamide, triethylenethiophosphamide, 6-mercaptopurine, 5-fluorouracil, mitomycin C and chromogranin A3 resistant cell lines.

The mechanism of action of erythromycin lies in the nucleic acid synthesis process of the cell, which binds directly to DNA and impedes DNA synthesis and DNA-dependent RNA synthesis reactions.